Question-and-Answer Session
Operator
(Operator instructions) And your first question comes from the line of Edward Tenthoff of Piper Jaffray. Please proceed.
Edward Tenthoff – Piper Jaffray
Great, thank you very much. Just one quick clarification on Frank's comment on Boehringer upfront and congrats on that deal, guys. Will that be on the second quarter? You said 2009 specifically.
Frank Karbe
Yes, well, we expect to recognize the entire upfront payment as revenue in the later part of this year.
Edward Tenthoff – Piper Jaffray
Okay, later part of this year. Great. And then Mike, you’ve said that the Avastin approval in glio certainly interesting based on the data that was presented. You see that as kind of a positive, how much that changed the landscape either for specifically for your compound, but just in terms of actually looking at pivotal studies and paths for illustration, does that actually make it more difficult to enroll patients or a higher bar, how do you kind of look at that in that way?
Mike Morrissey
Let me just comment on that briefly. I think first of all, the FDA’s decision to grant accelerated approval for Avastin and GBM is really great news for patients with this horrible disease and their families and caregivers. So it’s a big step forward for that population. The (inaudible) access clearly plays an important role in the tumor biology of GBM and Avastin is active in access at any good – we sort of look at other targets, other pathways are at play there and we think MET is very important member of that class family of targets that could actually help with GBM.
As we talked about preciously, MET is widely expressed and activated in many GBM tumors, and make – importantly continues to play an important role in driving that invasive phenotype that is seen in many patients with advanced disease. So I think you’ll see more about that in terms of the role that MET might play in GBM at our bio-market poster at ASCO in a few weeks.
Frank Karbe
I guess we were not overly surprised by the approval that was granted this week. So we've been tracking that area very closely, even before the ODAC meeting based on last year’s ASCO data. It was a pretty strong movement towards that being adopted as a model that could work in GBM. So we expected to see Avastin get accelerated approval based on improved – if you were looking at historical controls, but still from what modest increases in response rate and the ratio of response.
- To read the full transcript on Seeking Alpha, click here »
